Special Dinner Presentation
Meaningful Clinical Endpoints with ERG
Originally presented at a dinner event at ARVO 2022 entitled: “Meaningful Clinical Endpoints with ERG: Why Detecting Functional Change before Structural Change Matters”
The talk centered on the handheld and non-mydriatic RETeval Device for ERG testing that is rapid and non-invasive. ERG testing is an established biomarker to track both safety and efficacy endpoints for pharmaceutical or clinical research in the ocular space. The RETeval Device is therefore the ideal tool for conducting these types of studies.
Dr. Mitch Brigell, PhD presented on practical electroretinographic testing with the RETeval as both a clinical efficacy and a translational biomarker. It provides, for example, a functional measure of diabetic retinopathy risk progression that was more predictive than structural imaging. Likewise, functional testing of the ganglion cell layer (PhNR) provides an objecting measure of glaucoma.
Dr. Quentin Davis, PhD, presented on the scientific and logistical rationale for conducting clinical trials with ERG testing using the RETeval Device. The reliability and relatively inexpensive cost of the unit, combined with it’s rapid and non-invasive interface makes it ideal for safety and efficacy endpoint tracking in clinical trials related to ocular disease.
Presented By:
Quentin Davis, PhD
Quentin is Vice President of Operations and Development responsible for the technical aspects for the company’s UTAS and RETeval products. We often refer to him as the brains behind this transformational RETeval ERG device.
Quentin was previously involved in immunoassay, biological warfare detection, and in vitro diagnostic device development for 13 years before joining LKC in 2010. He was the project lead for the M1R electrochemiluminescence reader for IGEN International, the Head of Intellectual Property and Engineering Manager for BioVeris Corporation where he also served as mechanical lead for their M1M project. Prior to joining LKC, Quentin was the Engineering manager for Wellstat Diagnostics, where he was designing an in vitro diagnostic device. He is a registered U.S. Patent Agent and is an inventor on 18 U.S. patent applications.
Quentin holds BS, MS, and Ph.D. degrees from the Massachusetts Institute of Technology in Electrical Engineering and Computer Science. Quentin lives in Urbana, Maryland and spends his free time with his wife and four children, including twins! He engages his kids with household science projects ranging from solar balloons and icicle makers to windmills and hydroelectric power plants.
Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to